A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
Male patients with evidence of de novo mHSPC during the study period
Initiation of ARPI therapy during the patient identification period and within ±90 days from the mHSPC diagnosis
Age ≥18 years at index date (ARPI initiation for mHSPC)
Initiation of ADT and/or docetaxel therapy within ±90 days from index date
At least 90 days of EMR activity prior to the index date
At least 90 days of EMR activity post-index, unless the patient died earlier.
You may not be if
History of other primary cancers (except non-melanoma skin cancer)
Use of PARP inhibitors, chemotherapy (other than docetaxel), immunotherapy or radiopharmaceuticals prior to index date
Evidence of castration resistance (CR) flag in the database any time before the index date or up to 90 days after the de novo mHSPC diagnosis
Clinical trial participation during the study period.
Clareo Health | A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
